Shares of Heska Corp (NASDAQ:HSKA) have been given an average recommendation of “Hold” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $84.25.
Several research analysts recently issued reports on HSKA shares. ValuEngine lowered shares of Heska from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 3rd. Sidoti upped their price objective on shares of Heska from $72.00 to $77.00 and gave the stock a “neutral” rating in a research note on Wednesday. Raymond James cut shares of Heska from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. They noted that the move was a valuation call. BidaskClub cut shares of Heska from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $105.00 price objective (up from $75.00) on shares of Heska in a research note on Wednesday, November 6th.
Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in Heska by 1,229.0% during the second quarter. JPMorgan Chase & Co. now owns 21,876 shares of the medical research company’s stock worth $1,834,000 after buying an additional 20,230 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in Heska by 184.0% during the third quarter. State of New Jersey Common Pension Fund D now owns 28,400 shares of the medical research company’s stock worth $2,013,000 after buying an additional 18,400 shares during the last quarter. Metropolitan Life Insurance Co NY grew its stake in shares of Heska by 30.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,789 shares of the medical research company’s stock valued at $198,000 after purchasing an additional 646 shares during the last quarter. State Street Corp grew its stake in shares of Heska by 7.0% during the third quarter. State Street Corp now owns 297,775 shares of the medical research company’s stock valued at $21,103,000 after purchasing an additional 19,470 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Heska during the second quarter valued at approximately $219,000. 97.92% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:HSKA traded up $3.73 during mid-day trading on Thursday, hitting $101.72. The company’s stock had a trading volume of 877 shares, compared to its average volume of 60,763. Heska has a fifty-two week low of $62.47 and a fifty-two week high of $102.09. The company has a current ratio of 8.52, a quick ratio of 6.80 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $757.24 million, a price-to-earnings ratio of 71.62 and a beta of 1.10. The stock has a fifty day moving average of $95.74 and a 200-day moving average of $82.20.
Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Heska had a net margin of 3.15% and a return on equity of 3.17%. The firm had revenue of $31.24 million during the quarter, compared to analyst estimates of $30.44 million. On average, equities analysts anticipate that Heska will post 0.05 earnings per share for the current fiscal year.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Featured Article: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.